NLRP3 and major depressive disorder: Our results for the first time showed that Ori treatment reduced the expression of NLRP3 inflammasome components including IL-1β, NLRP3, ASC and Caspase-1 both in the hippocampus of the LPS-induced depression models and LPS-treated astrocytes, which was enhanced by autophagy agonist Rap and weakened by autophagy inhibitor 3-MA.